Als unabhängiges Forschungsinstitut informieren wir zu unserer Forschungstätigkeit, unseren Veranstaltungen sowie zu wichtigen Neuigkeiten aus unserem Netzwerk.
-- Phase III Secondary Endpoint Results Demonstrate A Significantly Higher Disease-free Survival Rate following nab-paclitaxel as Investigational Therapy in Neoadjuvant Breast Cancer --
Neu-Isenburg/Frankfurt, Germany and Summit, New Jersey — December 7, 2017 — The German Breast Group (GBG), the German Gynecological Oncology Working Group-Breast (AGO-B) and Celgene Corporation today announced long-term invasive disease-free survival results from the GeparSepto clinical trial comparing the investigational use of nab-paclitaxel (ABRAXANE®) to solvent-based paclitaxel in early high-risk breast cancer patients at the 2017 San Antonio Breast Cancer Symposium (SABCS). The results from the 1,206 patient study found that nab-paclitaxel demonstrated a significantly higher disease-free survival rate in high risk early breast cancer patients when compared to conventional solvent-based paclitaxel.
"nab-Paclitaxel at a dose of 125 mg/m² weekly is equally efficacious but less toxic than at 150 mg/m²"
Results from the neoadjuvant randomized GeparSepto study (GBG 69)" abstract P1-14-11
Updated Phase III Results from German Breast Group (GBG) Demonstrate Reduced Dose of Nab-Paclitaxel (ABRAXANE®) Maintains Efficacy while it Improves Tolerability in High-Risk Early Breast Cancer
SAN ANTONIO & NEU-ISENBURG, Germany & FRANKFURT, Germany -- The German Breast Group (GBG) said less may be more when it comes to the dose of innovative pharmaceuticals used to treat cancer. A follow-up to a Phase III trial presented at last year's San Antonio Breast Cancer Symposium (SABCS) demonstrated a lower dose of nab-paclitaxel (ABRAXANE®) (125mg/m2/week) maintains efficacy and is less toxic than a higher dose (150mg/m2/week) that was the starting point in the study. Both doses demonstrated improved efficacy compared to conventional paclitaxel, a taxane commonly used to treat many forms of cancer.
Press release, 5pm CT, Dec 9th, 2015
Adding Carboplatin to Presurgery Chemotherapy Improved Disease-free Survival for Patients With Triple-negative Breast Cancer Previous results from GeparSixto showed carboplatin also increased pathologic complete responses
SAN ANTONIO — Adding carboplatin to presurgery chemotherapy improved disease-free survival for patients with triple-negative breast cancer (TNBC), according to results from the randomized phase II GeparSixto clinical trial presented at the 2015 San Antonio Breast Cancer Symposium, held Dec. 8–12.
Press release, 3:15pm CT, Dec 9th, 2015
Abstract No: 1004, Monday June 1, 3:00 PM to 6:00 PM
Prediction of pathological complete response (pCR) by Homologous Recombination Deficiency (HRD) after carboplatin-containing neoadjuvant chemotherapy in patients with TNBC – Results from GeparSixto.
Abstract No: 51, Sunday May 31, 11:30 AM to 1:00 PM
PIK3CA mutation correlates with pathological complete response in primary HER2-positive breast cancer – combined analysis of 967 patients from three prospective clinical trials
Abstract No: 1008, Monday June 1, 3:00 PM to 6:00 PM
Relationship of omission of adjuvant radiotherapy to outcomes of locoregional control and disease-free survival in patients with or without pCR after neoadjuvant chemotherapy for breast cancer: A meta-analysis on 3481 patients from the Gepar-trials.